The US Centers for Medicare and Medicaid will provide expanded coverage for ocular photodynamic therapy with verteporfin [Visudyne] from 1 April 2003.

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 450, 2004-04-10 , pp. 15-15(1)

Publisher: Adis International

Keywords: Age-related-macular-degeneration, treatment; Healthcare-news; Novartis; Novartis-Ophthalmics; QLT; Reimbursement; Verteporfin, therapeutic use

Document Type: Short communication

Publication date: 2004-01-01

• In this: publication
• By this: publisher
• In this Subject: Pharmacology

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers